Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Maged Shenouda Buys 50,000 Shares

Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Maged Shenouda acquired 50,000 shares of the stock in a transaction dated Friday, May 16th. The stock was acquired at an average cost of $0.44 per share, with a total value of $22,000.00. Following the purchase, the chief financial officer now owns 138,335 shares of the company’s stock, valued at approximately $60,867.40. This trade represents a 56.60% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Maged Shenouda also recently made the following trade(s):

• On Tuesday, May 20th, Maged Shenouda bought 60,000 shares of Relmada Therapeutics stock. The shares were acquired at an average price of $0.52 per share, for a total transaction of $31,200.00.
• On Monday, May 19th, Maged Shenouda acquired 90,000 shares of Relmada Therapeutics stock. The shares were bought at an average cost of $0.49 per share, for a total transaction of $44,100.00.

Relmada Therapeutics Trading Up 17.3%

NASDAQ:RLMD traded up $0.09 during midday trading on Tuesday, reaching $0.60. The company had a trading volume of 1,386,935 shares, compared to its average volume of 913,305. The stock’s fifty day simple moving average is $0.34 and its 200-day simple moving average is $0.77. Relmada Therapeutics, Inc. has a 12-month low of $0.24 and a 12-month high of $4.47. The firm has a market capitalization of $19.82 million, a price-to-earnings ratio of -0.21 and a beta of 0.18.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.27). As a group, sell-side analysts expect that Relmada Therapeutics, Inc. will post -2.73 EPS for the current year.

Institutional Trading of Relmada Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its stake in Relmada Therapeutics by 535.5% during the fourth quarter. Renaissance Technologies LLC now owns 164,513 shares of the company’s stock worth $86,000 after purchasing an additional 138,625 shares during the last quarter. AdvisorShares Investments LLC grew its position in shares of Relmada Therapeutics by 206.5% in the 4th quarter. AdvisorShares Investments LLC now owns 210,068 shares of the company’s stock valued at $109,000 after buying an additional 141,540 shares during the last quarter. Tang Capital Management LLC raised its stake in Relmada Therapeutics by 295.1% during the 4th quarter. Tang Capital Management LLC now owns 200,825 shares of the company’s stock worth $104,000 after acquiring an additional 150,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in Relmada Therapeutics in the first quarter valued at $33,000. 45.24% of the stock is currently owned by institutional investors and hedge funds.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.